Operational Costs Compared: SG&A Analysis of GSK plc and Teva Pharmaceutical Industries Limited

GSK vs. Teva: A Decade of SG&A Trends

__timestampGSK plcTeva Pharmaceutical Industries Limited
Wednesday, January 1, 201482460000005078000000
Thursday, January 1, 201592320000004717000000
Friday, January 1, 201693660000005096000000
Sunday, January 1, 201796720000004986000000
Monday, January 1, 201899150000004214000000
Tuesday, January 1, 2019114020000003806000000
Wednesday, January 1, 2020114560000003671000000
Friday, January 1, 2021109750000003528000000
Saturday, January 1, 202283720000003445000000
Sunday, January 1, 202393850000003498000000
Monday, January 1, 20243702000000
Loading chart...

Data in motion

A Decade of SG&A: GSK vs. Teva

In the ever-evolving pharmaceutical industry, operational efficiency is paramount. Over the past decade, GSK plc and Teva Pharmaceutical Industries Limited have showcased contrasting trends in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, GSK's SG&A expenses have seen a steady increase, peaking in 2020 with a 39% rise from 2014. In contrast, Teva's expenses have decreased by approximately 31% over the same period, reflecting strategic cost-cutting measures.

Key Insights

  • GSK's Growth: GSK's SG&A expenses surged, particularly between 2018 and 2020, indicating potential expansion or increased operational activities.
  • Teva's Efficiency: Teva's consistent reduction in SG&A expenses highlights a focus on streamlining operations, especially post-2016.

These trends underscore the diverse strategies employed by these pharmaceutical giants in navigating market challenges and opportunities.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025